Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: stickmonkeytamer, Today 14:46
Last post: Salfordred, Today 18:38
Very sorry to hear that news , as you say there are many alternatives. Some close friends of ours were upset when their son exceeded the height for fighter jet, but he went onto other things, step brother in law wanted to fly and ended up in a very good position in air traffic controller position in Preswick . Positivity is the aim.
Not a good sign , last time I remember intense Aircraft hitting it hard was in the North Yorkshire moors , Pre gulf war .
No point in going against Putin , It's a split decision in the RSSR .
So sorry to hear that Bailiff; deciding what you want to do with your life is a big decision and it’s such a shame to have that dream taken away. Hopefully another door of opportunity will open up for your son very soon.
Thanks guys. He is gutted as has dreamt of little else but we’re being positive where we can and looking at other options he can pursue.
Yep, a nice kick up today. Somethings brewing……..
gla x
What a disappointment for your Son Bailiff but rest assured another door will open for him somewhere.
Am on the N.Norfolk coast at present and the boys from Lakenheath have been practising dogfights most of the week-jeez what a racket!! We can hear them taking off on a still day even though we are nearly 50 miles away.
Nice kick in the pants today-long may it continue
Started: TrickyEFC, Today 18:18
Last post: TrickyEFC, Today 18:18
Jun-24 16:27:35 40.00 50,000 Unknown* 20.00k
Good weekend all.
Started: GlenFidrich, 20 Jun 2024 15:13
Last post: colbaltblue, Today 16:52
Glen, whilst you did use quotation marks, a casual reader might think Lsesar was referring to potential mm actics next week; which he wasn't!
SOG- In this instance I think your last paragraph is a big ask, and very unlikely to happen. 😀
LseSar, factual evidence is my posting history of over 12years here. That is factual evidence sonny of my involvement with sareum. You have no proof of being here more than a recent couple of months.
Don't be a twat sonny takea day off and enjoy the rise thatmost of us long term holders expect at this stage in the game.
Glanfidrich - well of course I’m happy (happier) now! Why wouldn’t I be? Genuinely didn’t expect an uptick of over 18%, and I’ll also admit if it drifted 5% down today would have sold a chunk by Monday. So impatiently holding - 5 trading days left.
"Indeed the wait continues. My patience is holding out (barely) but I think the positive sentiment is beginning to wane and the mm will really go to work next week. We’ve all seen it here before being walked down." Happy now, Lsesar? Your laundry bill will be much diminished. Happily. Patience is the key, my friend.
Not so sure it was 'promised', but I would like to see it arrive.
Yes nice to see some FOMO let's hope the news arrives as promised next week
Could be speculators preparing for a possible announcement next week? Whatever the case it's a welcome up tick. LH&K Mafuta
Short-sellers squaring the books on a Friday afternoon or something more substantial?
Looks like MMs have decided its time to make money on all the recent sells theyve taken in
Either that or the FOMO is real and building again lol
Started: BasilAlderman, 3 Jun 2024 13:49
Last post: The-Oracle, Today 10:31
The board like any company like any company with competitors, have and will compare their product to others before and present.
We can only do the same and compare on past deals in the sector.
Yes and fingers crossed for all SAR investors. We are entering the most exciting period in the company's history. I am particularly buoyed by the fact that in the month's pre-and post the UKRI data for SDC-1801 being released in July 2021 the SAR share price climbed dramatically. This is the very same candidate that we are about to hear P1a results about. It certainly feels, to this seasoned SAR shareholder, that history is about to repeat itself. Hopefully, Tim and John's moment to shine on the global pharma stage is nearly here. Wishing everyone invested in SAR the best of luck over the coming days and weeks.
Morning Brighty ... What would you do if you were one of the above? ... the message is titled lets stick to the FACTS
Whilst technically what you have written makes the mouth water with possibilities of high end deals for SAR compounds we do need to show some caution and my reading of the outcome may be different from others
If I was a large pharma with a longish patent and multi-billion income who could potentially lose business from an up and coming new company with a potential better compound then it might be in my interest to purchase that company whilst still cheap for say £500M to protect my own company stream .... BUT ... if my patent was shortly expiring I would not necessarily wish to purchase another company with a new patent unless the product had been proven to work .. The risk/reward gamble in choosing a company at this point makes less business sense as I need to purchase a compound which is guaranteed to work ....
So for me the patents we have are only as good as the products ... lets prove the product then the patent gives the extra value IMHO
Exactly right. A company that targets psoriasis, psoriatic arthritis and Crohn’s disease facing a patent cliff of $10 Billion in annual sales is going to be looking at licencing or M&A activity to fill its patent gap. These expiry dates, as you point out, are the big driver for M&A decisions in our sector. The very good news for Sareum shareholders is that there are some very significant and noteworthy patents due to expire within the next 2-5 years, worth billions of pounds. In addition to your Johnson and Johnson suggestion I would also check out:
• Merck MSD’s Keytruda and our combo with 100% regression of tumours in lung cancer (2019). This is probably the standout opportunity. With reported annual sales of over $14.38 billion the patent expiration is 2028.
• Japanese based Takeda could be one to watch, especially with Tim Mitchell's existing links with the company via the obesity drug Oblean® (cetilistat), which he invented. Takeda's Entyvio patent expiration is just 2-3 years away in 2026. It has reported global sales of $4 Billion.
Another company exposed to the expiry of patents – and who therefore could be an acquirer of Sareum - is Bristol Myers Squibb. They potentially could be losing exclusivity soon of Revlimid, Eliquis and Opdivo.
• Revlimid has reported global sales of $12.1 billion and its patent expiration is said to be by 2026.
• Eliquis with reported sales of over $9 billion has a patent expiration between 2027 & 2029.
• Opdivo, with reported annual sales of over $6 billion has a patent expiration dated of 2028.
Other patents expiring soon and which could prove pivotal for SDC1801/1802 and SRA737 include:
• Novo Nordisk’s Victoza, with reported annual sales of $3 billion. Patent expiration date imminent.
• Novartis’ Cosentyx with reported annual sales of $4 billion has a patent expiration of between 2025 / 2026.
• Amgen’s Prolia/Xgeva and its reported annual sales of $4 billion has a patent expiration of: 2025 / 2026
• Eli Lilly’s Trulicity patent expiration date is between 2027 to 2029. Trulicity has reported annual sales of $5 billion+.
• Merck’s Januvia & Janumet patent expiration date is imminent. Januvia & Janumet has reported sales of $5 billion+.
• Pfizer’s Ibrance with reported annual sales of over $5 billion has a patent expiration date of 2027
• GSK’s Dolutegravir with global annual sales of approx $6 billion has a patent expiration of between 2027 to 2029
• Regeneron /Bayer’s / Eylea has a patent expiration date of 2026. Eylea’s latest reported annual sales are $8.36 billion.
In summary, £ Billions in lost sales. What would you do if you were one of the above? You would licence or takeover the company with the replacement drug and with all its global patents / IP ducks in a row. Who would that be? Step forward Sareum.....
Good luck, Brighty
As my old Physics teacher used to say ... "empty vessels make the most sound" ... it would be wise to view the data which will be incoming soon before making wild and sweeping statements that none can substantiate ... but I guess impatience is a feature of waiting a long time ... me? I can wait the finishing line is in view ... LH&K Mafuta
Nothing really matters until we get news, lots of noise currently with no meaning. Play nicely people.
Started: carter19, 20 Jun 2024 12:38
Last post: dramallama, 20 Jun 2024 17:14
I’m just happy to be able to get my average down, from 260 to 43p so far
Not all of the red trades are sells as we all know. Buyers want the shares cheaply so will always put in a low price. MMs obviously happy to oblige.
Just the way that it is
I don't agree. I'm very disappointed with the decline of the SP. It's always the same with Sareum.
In my opinion, I think it’s holding rather well.
Laz - I’m sure there will be traders who will buy in, just wonder if there will be the volume to push up. Despite us being in a great space with our compound and up to date positive signals from Tim, we just aren’t getting the momentum to break out. I know the evangelicals here will pour scorn on anything but dreamy comments but the reality currently is a near 20% drop in the last couple of weeks (still 300% above 10p buy in though) Interesting thing is apparently everyone is still buying and “topping up”. - Quick Look at trades and the sea of red says otherwise for today
Started: HotblackDesiato, 18 Jun 2024 18:37
Last post: Gunner68, 20 Jun 2024 10:47
I agree with you potnak 1802 once/if 1801 is validated with low tox and potential to be best in class we would definately see more interest especially if 1802 indications are for cancer I wonder if there would be combo trials which seems to be the way forward
GLA
Hi Krusty, I have always wanted SAR to go for P2 on their own but the only option for funding would mean dillution for existing shareholders and personally I'm throwing any more large sums at this. I am still buying but it's only disposable income each month. I really do think the board need to step up and prove they can negotiate a deal for 1801. The business model is and has always been to licence at pre or early clinical stages. Thats where we are right now. Any pharma will know the cash runway is getting shorter so I don't think we are in a great negotiating position so upfront might be where we have to compromise. However, if 1801 is with a n other pharma then even a modest upfront of say £5 to £10 million will be enough to get 1802 ready for trials. That would, for me be an amazing deal. The biggie has always been 1802.
Well each day with no update provokes more small lot selling which gives MMs just the reason they need to lower the price
I would prefer not to receive good news when the share price has sunk into the 20s
(and no, this isnt any kind of deramp)
You're spot on Lsesar. One day all the talk of "the science" and the much expected positive RNS may happen hopefully we will have some cash left in here to benefit from it.
Bobbler - I’m conveying where I am with the whole rns release we are all waiting on - not de-ramping
This is one of your posts:
“If it spikes at £10 there will a lot of people with a serious spike in their blood pressure!”
Would this be considered a ramping attempt? Sure I told you before filter me, or if that’s not working just ignore me please.
Started: sadoldgit, 20 Jun 2024 08:31
Last post: sadoldgit, 20 Jun 2024 08:31
Started: sadoldgit, 19 Jun 2024 15:29
Last post: sadoldgit, 19 Jun 2024 15:29
Have posted before but the link indicates the areas and competition that we face.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959504/
Thanks for the clarification Billy - Good luck whatever you decide
Good luck, Billy. Looks like you are timing it right. I thought we might see a blue day today, in case of a Thursday RNS. If not Friday might see a drop.
Lazarus2 and Potnak, that buy wasn't me. I'm hovering with £40K to spend here, just waiting to see if the share price has settled or if it going to drop any further before I pull the trigger.
Bill
Yeo, Billy, don't want out him but he is probably the biggest investor here. He holds more than the the board members.
I think you are correct Potnak. It was Billy that stated he was buying I believe. Credit to him.
Started: Brighty1, 19 Jun 2024 07:46
Last post: steve196, 19 Jun 2024 10:48
Any idea how much their average is now 🤔
They did.
What I don't understand is, why don't HNWI average down when it was around the 10p mark.
It will be along time before it's get to their buy in price.
Unless the trails are excellent.
If the compound and 1a data is good, we won't need HNWI investment and the dillution that brings. We should get a licenced, as per the RNS.
If the compound and 1a data is good. We won't n
Started: sadoldgit, 19 Jun 2024 08:03
Last post: sadoldgit, 19 Jun 2024 08:03
Interesting link below. Good for overview
https://www.linkedin.com/pulse/baricitinib-market-global-outlook-forecast-2022-2028-share/
Unfortunately it does not give any indication of dollar revenues.
In a separate link.
Deucravacitinib generated 66 million dollars in the last quarter of 2023. 62 million of this was in the US.
This equates to approx 250 million dollars a year, not bad for an inhibitor that can be bettered in efficacy for Psoriasis and duly failed to meet either of its 2 end points in Ulcerative Colitus
It is very difficult to try to establish any ball park figure of a potential value for 1801 as we need some idea of potential Indications.
We should be able to better Baricitinib in at least regards to SAE's
Interesting also to note that Baricitinib was also hailed as the first and only kinase inhibitor NDA approval for covid19.
Regards
Last post: Celtic007, 18 Jun 2024 19:32
So it went up, it’s gone down. We’re waiting for news. Got it. Some thing never change but glad to see a few familiar faces
Welcome back Hopkirk
KR
ZA
Tricky, your lack of punctuation, seriously lol
Good to have you back! Really 4 years wow where has time gone. I hoped to be sold up by now.
Welcome back
Nice to see you post again Hoppy.
Hopefully we are on the verge of a very positive RNS
Started: Lazarus2, 18 Jun 2024 09:49
Last post: The-Oracle, 18 Jun 2024 17:18
Or they might just take a portion of their salary come payday next week and pile in.
47 to 30 is nothing against results.
Crap results and it's a loss.
Excellent results as we hope and expect and it's to the moon. Sareum has done it before, we are further ahead and can do it again. If it's delayed by 2 weeks eg, it means nothing. Probably the T's and I's because someone fell ill. If they have the results, they have to Rns, if they don't, the results are neither good nor bad, just unknown.
Sell, buy or hold, or overfocus on SP that has nothing on the results. Could be a loss either way. Sell and wake up to 100 and hate yourself, buy and wake up to 0.05 and hate regret. Gl
If you want to sell, just do it. People are waiting to buy in lower. I will top up in 2 days if no Rns and the price is right.
If, ifs and buts were pots and pans, you wouldn't need a tinker man.
This time next year Rodney.
Sorry for incomprehensible posts. A mixture of predictive texts and a phone screen that is starting to die, I think.
If no news next week. I think some holders will get itchy feet, especially if they bought around 10p. The drop from 47p is already a bitter pill to swallow and I think we have lost some if the new investors already. It certainly doesn't is, quieter in this group. Having said all that. I've go a feeling that we will get something this week.
Do you mean"no red days after that" ?
Started: sadoldgit, 18 Jun 2024 10:00
Last post: lutonnews, 18 Jun 2024 12:19
don't worry
the sar rocket is being primed ready for launching at a secret location not far from the portobello road.
doc holliday and mr o are among the crew. just waiting for a red dot to ignite the lift off.
what could possibly go wrong ?
oh eck, i have just seen higgs climb into the ****pit.
Welcome to sareum.
Always drops between news.
Often doesn’t recover fully, too.
Aber - I can assure you that it is not Ostrich mentality. The next news will be the Trial results. You obviously know that. (unless 737 comes in from left field which I doubt)
If you are here as a bit of a flutter then fine. I have made my position and views clear. It is not advice, just a personal view based on believing in what Sareum are trying to achieve as opposed to what the spivs would have us believe. Good luck anyway
47p a couple of weeks ago now down to 32p today... I know some are saying follow the science and don't worry about the SP ... but that is ostrich mentality !! ... It is better to have an elevated SP prior to news if we want a higher SP after news
We need some form of news inbound ... I hope the silence is down to the BOD working on deals in the background, especially as TM and JR are being paid almost £20K each per month !!! and Parker £10K
Woodlands that should have read, apologies.
Must be a massive sale early this morning, or last night. Couldn't buy under 37 yesterday.
All will be revealed in time.
Last post: sadoldgit, 17 Jun 2024 19:34
Of course shares can go up and down and that is stating the obvious.
However he is also stating what he thinks may happen on the receipt of a poor phase1 trial RNS.
That is not quite the same.
At the moment he is not invested.
Essentially he was saying shares can sometimes go up or down……very profound
Krustysmegma,
I am inclined to agree with you very strongly. Perhaps it is not the most ill informed, but contrived yo serve a purpose.
What is the posters objective for posting such a post.
Primarily he has no shares at the moment and yet states it will buy back if the news is good.
However, which way we look at it, it is somebody who intends to buy back in.
On the release of good news this individual will need to be quick as will rise like a rocket.
As for any bad news, I ask the question on what factual or indeed basis of debate postulate that we may recieve bad news?
What would be the cause?
Tim and Co extremely confident of good results.
Mentions of best in class.
Very good at chemistry they are. Very experienced. I would definitely take that as a very positive indication, as to the success of 1801 data results, over and above the unsubstantiated drivel posted here..
Regards
Been hybernating until trial results - sometime soon I think - but are we expecting a big chunk of cash from CR fund too?
I think in all my years of reading posts on this board, this one might be the most ill-informed, badly thought through I've ever read. This has been posted by someone who clearly doesn't have a clue about SAR, or done the most basic research, and who has a strategy that is guaranteed to fail. Anyway, good luck, hope it works out for you after all your hard work.
Started: Silverfoil13, 16 Jun 2024 22:50
Last post: Lsesar, 17 Jun 2024 15:54
Bobbler - ramblings yeah ok, multiple personalities yeah ok, contradictory views in one post yeah ok…. And… now what. Just filter me please. I can’t do the unabated enthusiasm which some have here. Sareum can be summed up nicely by Gattuso “ Sometimes maybe good, sometimes maybe ****”
I certainly can't disagree with the good strategic planning.
Without wishing to appear overly blunt the BoD cannot see past the end of their noses. Add a splash of naivety and hey ho we were in a severe mess, nigh right up 5hit street Without a paddle.
Now fortunately we are recovering
Clearly the BoD have not looked far enough into the future. Have coped before in a buoyant market but from Feb 22 difficulties with financing rose.
On the plus side we don't appear to have any problems with adverse events.
The only indication we have at the moment is Psoriasis. Should be able to better Deucravacitinib in the PASI 75 score.
Looking at achieving better score over 12 weeks than Deucravacitinib over 16 weeks, with of course similar tolerability and safety profile.
This is about all we can say we nigh have under the belt at the moment.
Finance of some sort will be needed and Sareum look to be pursuing non dilutive means.
Phase 1 results will see a rise in my opinion. Accessing likely non dilutive funding and details therefore will at the very least maintain SP climb until further positive news.
On no news of non dilutive funding the SP likely to follow the trajectory that has occurred in the past and a slow retrace.
My own opinions of course.
There is a lot l believe going on which the BoD either can't or won't let on.
The good old days of the transformational change that did no quite materialise where the Sp dropped around 60 % max on the day.
Tim got slated for this hence now there exists silence.
Regards
Psoriasis Deucravacitinib is available as a treatment on the NHS it is also available to purchase.
The ramblings of someone with multiple personalities. Not sure if you could get anymore contradictory views into one post!
SOG - Very interesting read. Looking at the reasons why drugs fail:
Analyses of clinical trial data from 2010 to 2017 show four possible reasons attributed to the 90% clinical failures of drug development: lack of clinical efficacy (40%–50%), unmanageable toxicity (30%), poor drug-like properties (10%–15%), and lack of commercial needs and poor strategic planning (10%)
We appear to have very low toxicity indicated but I don’t think we have good strategic planning (sorry bod don’t inspire me when it comes to business savvy). Clinical efficacy will begin to be demonstrated in phase 2 on ward.
Those who have the stomach to continue to hold for the next rns on phase1 results stand to see a l least 100% rise from todays price if positive (could easily be more dependant on if the bod have a deal).
Those who wish to bail, jump -if it come good best of luck just trying to get back in at todays prices, it will be a multiple of todays 40p
Those who are holding , hold - just try to sell quickly if it’s negative news, Sub 1p easily achievable
Potnak you are not very scientific, or have any scientific understanding which is confirmed by the gibberish you write at times.
You state one moment that we all need to understand that there is a 75% failure rate in Phase 1 trial, based on something you seemed to have read. Then you follow up with you seemed to remember reading about 75% of drugs never get past phase 1.
Without wishing to appear pedantic which of the two statements you made are true.
You based your first statement as fact. The 75% failure rate in phase1.
This is clearly incorrect as l have pointed out and given guidance for further info to peruse.
As for not going to read it all? Why not?
All you in effect do is feed the negative numpties over on ADVN with a source to undermine.
I have never picked on a poster that has demonstrated even the slightest scientific knowledge.
I did an OU Science degree many moons ago, I worked in engineering in the early part of my career.
At the age of 24 l was a field service engineer installing, repairing and retrofitting corrugated cardboard manufacturing equipment weighing anything up to 200 tonnes.
I worked nigh 3 years on research and development in engineering.
An enjoyable at times job but difficult when on your own.
99% of any investigational work carried out is down to precision and accuracy. Each individual component needs an understanding of its strong points and weak points.
Almost good enough is never good enough, hence failure.
There is no intention from me to stamp my superior knowledge on anybody.
What l will do is challenge statements that are not only false and misleading but also unsubstantiated with no proper resource to back it up.
With regards to not posting anything negative, l will be diplomatic and say you have not posted anything positive either.
My opinion for what it is, is that you are trading at the moment. I have nothing against this.
What l am against is up and down posting. One minute pointing out 1 to 2 billion company value at one time then introduce 75% risk of failure on the other hand.
You sir, are unbalanced to say the least.
I am 100% certain in the belief that the outcome will prove satisfactory for further trial such as phase2a, what l am not 100% certain about is the full scope of side effects or the full data results of biomarkers.
These will have significant effects as to the value of SDC1801.
Regards and enjoy a couple of days off.
Started: colbaltblue, 17 Jun 2024 12:43
Last post: Aberystwyth, 17 Jun 2024 14:49
Many Thanks Ronnie - much appreciated
Cobalt. Bottom left, tap 'cookies' then turn off all concents, go right down the page and agree, or whatever it says...... and most of the carp adverts will disappear.
Stop? Will there be any FOMO? At this rate we'll be lucky to get back to 50p. Will my screen ever stop jumping about or be filled with carp adverts?
Is this ever going to
Last post: sadoldgit, 17 Jun 2024 10:14
Unfortunately it does not quite work like that tricky.
It would be good if it did.
Regards
If we have a few more buys than sells and we will jump 5%
Got to work both ways 🤪
Last post: sadoldgit, 17 Jun 2024 07:16
Funny Guy on what factual basis do you make such absurd statements.
What has notification of the on licensee to do with SRA737 advancement.
As for 182 it does not exist.
1801 we await final data analysis results. Could be tomorrow next week or next month. Bit it will come and the Indications are it will prove successful.
SDC1802 whilst being developed in preclinical stage for oncology there have been recent patent applications for 1802 to be used as am immunotherapy. Clearly there is significant benefit here.
If you doubt this then please provide satisfactory evidence to substantiate your statement.
Next thing you will be stating is this will be going down to 10p again as you have proven history of.
Regards
There is no cat in hell chance there will be an imminent notification of SRA 737 advancement, they have not even said who the license is with and very little if any money has been paid.
There is very little chance of a license for 182
i think people are really jumping the gun
HBD, I do not think they would have agreed the new licence without a belief that 737 would be progressed, they are motivated by both finding solutions for this terrible condition (I know from posts that this was of the reasons for investment as well as looking to make a return, this was certainly one of my non financial reasons for investing)and generating more money to invest in research. On 737 I choose to believe that we will get real news, hopefully soon though it does worry me slightly that there has been a significant period for them to fund raise and in the US market raising funds is normally a fairly quick process...anyway time to watch England GLA
It certainly looks like someone intentionally applied the brakes to 737 development, SOG. Although we'll never know the absolute truth of the matter, you'd hope when negotiating the latest deal that the CPF would try to ensure some level of urgency in moving 737 to the next stage. Perhaps that's just an idealist's point of view though.
On the brighter side, 1801 news must be just about peeking over the horizon - set your sp compass to head north from here!
Good evening HbD,
There was another that did not make sense at the time.
My own opinion is that it were scuppered.
Sierra Oncology stated at the time.e that 737 could prove more commercially viable than Momoletonib.
Developments and then silence. Then we here takeover by GSK.
A year later they hand it back most likely as of the clause within contract requiring return of 737 if no developments in a 12 month period.
Basically they strung it along from the end of 2019 to end of 2022.
3 years!
GSK would certainly not want a competitor to have it as would pose a serious threat to the drugs that were the Tesaro pipeline they paid 5.1 billion for a year earlier.
It will come out one day.
GSK paid billions before due to mal practices.
I have posted much on this subject before.
Hi SOG - no matter how frustrated we punters are with the glacial progress of 737, imagine how Tim & John feel. They must be tearing their hair out.
Taken from the link posted earlier.
Link is from early 2020
NEWS: In a new study, scientists have found that small molecules that stop cancer cells from copying their DNA can boost the effectiveness of another type of cancer drug called CHK1 inhibitors.
This could offer a new, effective way of treating cancer by combining two drugs.
💬 Study co-leader Professor Michelle Garrett, previously a Team Leader at the ICR, explains:
“Our study shows the potential of targeting DNA replication for adding to the effect of an existing drug that blocks a system that helps respond to DNA damage."
I do find it very odd that on this type of news that CHK1 ceased development at the same time as Nick Glover resigned.
Started: Krone, 15 Jun 2024 21:59
Last post: mike001, 16 Jun 2024 14:55
When you analyse these two statements they are actually so open beyond comprehension.
This one was hilarious!
Principle 2 – Seek to understand and meet shareholder needs and expectations.
Sareum is committed to open communication with all its shareholders.
Highlighting great near term potential!
CHAIRMAN'S STATEMENT
Sareum has made good progress during and after this period progressing its lead clinical asset, SDC-1801, through a Phase 1a study. The single ascending dose (SAD) part and the food effect study of SDC-1801 have progressed well, giving the Company continued confidence over the clinical momentum in the trial and optimism as we move towards the completion the study.
The multiple ascending dose (MAD) portion of SDC-1801 is nearing completion. Sareum aims to conclude this part of the trial by the end of Q2 2024. Subject to data review, additional funding and/or potential licencing opportunities, we endeavour to be in a position to commence a Phase 2a study in psoriasis patients before the end of 2024.
It is becoming increasingly clear that the TYK2/JAK1 class offers great potential for the treatment of autoimmune disease, with potential for broad coverage and increased efficacy across key targets, lower toxicity and potentially stronger efficacy. We believe SDC-1801 has the potential to be a best-in-class TYK2/JAK1 inhibitor for autoimmune diseases and we're excited about its progress in this ongoing clinical study. While the MAD study is still in progress, interim data shows that levels of SDC-1801 in blood are already in the expected therapeutic range, and achieve concentrations greater than those predicted to reduce signalling of cytokines dependent on TYK2 and/or JAK1 activity by 50% for a sustained period following once daily oral dosing. Safety data remains blinded, but no serious adverse events have been reported to date.
We were also encouraged that, after the period end, Sareum's co-development partner, the CPF entered into a development and commercialisation license agreement for SRA737 with a private biopharma company based in the US. We are delighted that a partner has been identified to take this molecule forward into further development.
Started: The-Oracle, 15 Jun 2024 09:03
Last post: The-Oracle, 15 Jun 2024 09:03
Small delay here and there, matters not. Quality of the results, Yes. The big fish are watching.
Everything so far appears to be fine, plus I am always encouraged when I think back to Tim and Co taking the initiative, with the hasty set up down under and getting on with a sense of urgency. I want to believe that urgency and spirit is still alive. They have a lot to gain and so do we. Science afterall not funding is where they are in command.
Everyone's waiting for payday, likely the last chance to buy in this low for the rest of your lives. Gla